Sei Investments Co. Purchases 12,041 Shares of Insulet Co. (NASDAQ:PODD)

Sei Investments Co. increased its position in shares of Insulet Co. (NASDAQ:PODD) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 72,166 shares of the medical instruments supplier’s stock after acquiring an additional 12,041 shares during the quarter. Sei Investments Co. owned about 0.10% of Insulet worth $18,840,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. boosted its stake in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 56 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the period. Friedenthal Financial bought a new stake in shares of Insulet during the 4th quarter valued at $57,000. Finally, Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 246 shares during the period.

Insulet Stock Down 1.7 %

Insulet stock opened at $260.27 on Friday. The company has a fifty day simple moving average of $272.03 and a 200 day simple moving average of $258.25. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a market cap of $18.28 billion, a P/E ratio of 44.95, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Royal Bank of Canada started coverage on Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Piper Sandler upped their target price on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company lifted their price target on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.